Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis

Hernan Nicolas Lemus, Arthur E. Warrington, Aleksandar Denic, Bharath Wootla, Moses Rodriguez

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

A single peripheral dose of CNS-binding IgMs promote remyelination and preserve axons in a number of animal models of neurologic disease. A myelin-binding recombinant human IgM (rHIgM22) is presently in a safety trial in MS patients following an acute MS exacerbation. rHIgM22 (directed against oligodendrocytes) or rHIgM12 (directed against neurons) were administered to mice with MOG-induced experimental autoimmune encephalomyelitis (EAE) with study endpoints: Clinical deficits and brain and spinal cord pathology. IgMs were administered at a therapeutic dose of 100 μg intra peritoneal at the time of immunization (day-1, 0, +1), disease onset (15 days) or peak of the disease (28 days). Disease course was not worsened by either human IgM regardless of the time of treatment. Of note, the human IgM that recognizes a carbohydrate epitope on gangliosides and NCAM, rHIgM12, reduced brain pathology when given at time of immunization or at onset of disease, but did not reduce clinical deficits or spinal cord disease burden. Hence, treatment with rHIgM12 resulted in marked reduction in meningeal inflammation. Data consistent with the hypothesis that in the EAE model this molecule has an immune-modulatory effect. Treatment with an anti-CD4 blocking IgG prevented both clinical course and CNS pathology. This pre-clinical study further supports the safety of therapeutic CNS-binding human IgMs in the presence of autoimmunity and clearly differentiates them from IgGs directed against MOG or aquaporin-4 that worsen neurologic disease.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalHuman Antibodies
Volume25
Issue number3-4
DOIs
StatePublished - Apr 24 2017

Keywords

  • Experimental autoimmune encephalomyelitis
  • Human antibody
  • Inflammation
  • Myelin oligodendrocyte glycoprotein

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis'. Together they form a unique fingerprint.

  • Cite this